Benvenuto G Pernis

Author:

Benvenuto Pernis

ISBN #:

0124427030

Author:

Benvenuto Pernis

ISBN #:

0124427049

Author:

Benvenuto Pernis

ISBN #:

0124427502

Author:

Benvenuto Pernis

ISBN #:

0306442582

Author:

Benvenuto Pernis

ISBN #:

0125518501

Author:

Benvenuto Pernis

ISBN #:

0125518552

Author:

Benvenuto Pernis

ISBN #:

0125518609

US Patent:

20030103988, Jun 5, 2003

Filed:

Oct 26, 1995

Appl. No.:

08/548595

Inventors:

LEONARD CHESS - SCARSDALE NY, US
RANDLE WARE - NEW YORK NY, US
HONG JIANG - NEW YORK NY, US
BENVENUTO PERNIS - BRONXVILLE NY, US

International Classification:

A61K039/395
A61K039/38
A01N001/02
A61K039/00

US Classification:

424/184100, 424/810000, 435/002000

Abstract:

The level of CD8 T cell cytotoxicity directed toward activated CD4 T cells expressing a specific T cell receptor V chain and a major histocompatibility complex class Ib molecule is assayed by contacting a sample containing CD8 T cells with the activated CD4 T cells for a determined period of time and determining the amount of activated CD4 T cell death during the time period. The level of CD8 T cell activity stimulated by the activated CD4 T cells is assayed by measuring lymphokine release from stimulated CD8 T cells or by determining the amount of cell surface molecules specifically expressed on stimulated CD8 T cells. An agent capable of stimulating or inhibiting CD8 T cells cytotoxicity toward the activated CD4 T cells will suppress or inhibit the suppression of an immune response mediated by the activated CD4 T cells, respectively.

US Patent:

56249381, Apr 29, 1997

Filed:

Jul 18, 1994

Appl. No.:

8/276259

Inventors:

Benvenuto G. Pernis - Bronxville NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A01N 4342
A61K 3147

US Classification:

514313

Abstract:

This invention provides a pharmaceutical composition which comprises an amount of chloroquine effective to block MHC Class I recycling and an amount of a CD8+ T cell stimulatory agent effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, and a pharmaceutically acceptable carrier. This invention provides a method for treating an autoimmune disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the autoimmune disease. This invention provides a method for treating cutaneous lymphoma disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the cutaneous lymphoma disease. This invention provides a method for treating rheumatoid arthritis in a subject which comprises administering to the subject an amount of the pharmaceutical composition of chloroquine and a CD8+ T cell stimulatory agent effective to treat rheumatoid arthritis. Finally, this invention provides a method of depleting CD4+ T cells which comprises contacting to the cells an amount of chloroquine effective to block MHC Class I recycling and a CD8+ T cell stimulatory agent in an amount effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, so as to thereby deplete CD4+ T cells.